Marlborough, MA, United States of America

Richland Wayne Tester

This inventor holds 30 USPTO granted patents and 5 published patent applications, plus 6 CIPO patents and 4 EPO patents. Top assignees: Celgene Avilomics Research, Inc., Celgene Car LLC, Avila Therapeutics, Inc.. Active years: 2011-2022.

USPTO Granted Patents = 30 (Patent Applications = 5)

% Patents Active = 56.7

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 5.3

ph-index = 12

Forward Citations = 683(Granted Patents)

Company Filing History:

19 out of 44

Celgene Avilomics Research, Inc.

Avila Therapeutics, Inc.

patents

Years Active: 2011-2022

Loading Chart...

Areas of Expertise:

Kinase Inhibitors

Epidermal Growth Factor Receptor

Pyrimidines

Diaminopyrimidines

Heteroaryl Compounds

BTK Inhibitor

Protein Kinase Inhibitors

Substituted Pyrimidines

Salts

Chemical Compounds

Pharmaceutical Applications

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11351168 - 2,4-disubstituted pyrimidines useful as kinase inhibitors (2022-06-07),

2. 11292772 - Salts of an epidermal growth factor receptor kinase inhibitor (2022-04-05),

3. 10828300 - Substituted 2,4-diaminopyrimidines as kinase inhibitors (2020-11-10),

4. 10596172 - 2,4-disubstituted pyrimidines useful as kinase inhibitors (2020-03-24),

5. 10570099 - Salts of an epidermal growth factor receptor kinase inhibitor (2020-02-25),

6. 10010548 - 2,4-disubstituted pyrimidines useful as kinase inhibitors (2018-07-03),

7. 10005738 - Salts of an epidermal growth factor receptor kinase inhibitor (2018-06-26),

8. 9987276 - Substituted 2,4-diaminopyrimidines as kinase inhibitors (2018-06-05),

9. 9604936 - Besylate salt of a BTK inhibitor (2017-03-28),

10. 9549927 - Heteroaryl compounds and uses thereof (2017-01-24),

11. 9540335 - Salts of an epidermal growth factor receptor kinase inhibitor (2017-01-10),

12. 9415049 - Heteroaryl compounds and uses thereof (2016-08-16),

13. 9409921 - 2,4-disubstituted pyrimidines as kinase inhibitors (2016-08-09),

14. 9393246 - 4,6-disubstituted pyrimidines as kinase inhibitors (2016-07-19),

15. 9296737 - Substituted 2,4-diaminopyrimidines as kinase inhibitors (2016-03-29),

Title: Richland Wayne Tester – Innovator in Kinase Inhibitors

Introduction

Richland Wayne Tester, based in Marlborough, MA, is a prominent inventor with a remarkable portfolio of 30 patents. His contributions to the field of pharmaceutical sciences, particularly in developing kinase inhibitors, have significantly advanced medical research and treatment methodologies.

Latest Patents

Among his latest innovations are two notable patents:

1. **2,4-Disubstituted Pyrimidines Useful as Kinase Inhibitors** – This invention focuses on 2,4-disubstituted pyrimidine compounds that serve as effective kinase inhibitors. The associated compositions and methods for their use offer valuable therapeutic avenues in treating various diseases.

2. **Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor** – This patent presents a salt form and related compositions that inhibit EGFR kinases, demonstrating desirable characteristics for therapeutic applications.

Career Highlights

Richland has played a vital role in several respected companies throughout his career, including Celgene and Avilomics Research, Inc. His expertise and innovative approach to pharmaceutical research have positioned him as a key figure in the development of effective medical therapies.

Collaborations

Throughout his career, Richland has collaborated with notable professionals, including Juswinder Singh and Russell Colyn Petter. These partnerships have enhanced the innovative processes and outcomes in his research endeavors.

Conclusion

Richland Wayne Tester continues to make significant strides in the field of pharmaceutical innovation through his patents and collaborations. His work in developing kinase inhibitors is paving the way for future advancements in targeted therapies, showcasing the lasting impact of his contributions to the medical community.